Zalcitabine

A summary of the most common chemical descriptors (InChI Key and SMILES codes) for Zalcitabine are summarized together with 3D and 2D structures and relevant physico-chemical properties.

What is the Zalcitabine?

The molecule Zalcitabine presents a molecular formula of C9H13N3O3 and its IUPAC name is 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one.

Zalcitabine (dideoxycytidine) is a nucleoside reverse transcriptase inhibitor (NRTI) used as an antiretroviral drug in the treatment of HIV infection and AIDS. Zalcitabine was the third antiretroviral drug approved for use in the United States, after AZT (zidovudine, Retrovir) and ddI (didanosine, Videx). Zalcitabine is no longer manufactured or marketed..

Zalcitabine was first synthesized in the early 1980s. In vitro studies showed that zalcitabine was a potent inhibitor of HIV-1 replication. Zalcitabine was initially tested in humans in 1986. The first large clinical trial of zalcitabine was conducted in 1988. This trial showed that zalcitabine was effective in reducing HIV-1 viral load and increasing CD4+ T cell counts in people with HIV infection..

Zalcitabine was approved for use in the United States in 1992. The recommended dose of zalcitabine was 3 mg twice daily. In 1995, the dose was increased to 3 mg three times daily..

Zalcitabine was generally well-tolerated. The most common side effects were nausea, vomiting, diarrhea, and abdominal pain. Zalcitabine also caused a distinctive rash that was usually mild and resolved with continued use of the drug..

In 1996, the results of two large clinical trials, DDC-002 and DDC-HIV-007, were published. These trials showed that zalcitabine, in combination with other antiretroviral drugs, was associated with an increased risk of death. As a result of these findings, zalcitabine was no longer recommended for use in combination with other antiretroviral drugs..

In 1998, the manufacturer of zalcitabine, Hoffmann-La Roche, announced that it was discontinuing production of the drug. Zalcitabine was no longer available in the United States after December 31, 1998..

3D structure

Cartesian coordinates

Geometry of Zalcitabine in x, y and z coordinates (Å units) to copy/paste elsewhere. Generated with Open Babel software.

2D drawing

 

Zalcitabine WREGKURFCTUGRC-POYBYMJQSA-N chemical compound 2D structure molecule svg
Zalcitabine

 

Molecule descriptors

 
IUPAC name4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
InChI codeInChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
InChI KeyWREGKURFCTUGRC-POYBYMJQSA-N
SMILESNc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1

Other names (synonyms)

IUPAC nomenclature provides a standardized method for naming chemical compounds. Although this system is widely used in chemistry, many chemical compounds have also other names commonly used in different contexts. These synonyms can come from a variety of sources and are used for a variety of purposes.

One common source of synonyms for chemical compounds is the common or trivial names, assigned on the basis of appearance, properties, or origin of the molecule.

Another source of synonyms are historical or obsolete names employed in the past, however replaced nowadays by more modern or standardized names.

In addition to common and historical names, chemical compounds may also have synonyms that are specific to a particular field or industry.

  • .beta.-D-2',3'-Dideoxycytidine
  • .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
  • .beta.-D-DDC
  • 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine
  • 2', 3'-dideoxycytidine
  • 2',3'-DIDEOXYCYTIDINE
  • 2',3'-Dideoxycytidine & Interferon.alpha.
  • 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate)
  • 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein)
  • 2,3-dideoxycytidine
  • 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine
  • 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE
  • 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
  • 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one
  • 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
  • 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
  • 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
  • 481D892
  • 6L3XT8CB3I
  • 7481-89-2
  • A838234
  • AC-824
  • BCP13878
  • BD164564
  • BDBM50145605
  • BPBio1_001378
  • BRN 0654956
  • BSPBio_001253
  • C07207
  • C76390
  • CCG-101050
  • CCRIS 692
  • CS-1110
  • Cytidine, 2',3'-dideoxy-
  • Cytidine, 2',3'-dideoxy- & Colony-stimulating factor
  • Cytidine, 2',3'-dideoxy- & Interferon.alpha.
  • D 5782
  • D00412
  • D3581
  • DB-019728
  • DB00943
  • DDC (DDC)
  • DS-4152 & ddC
  • DSSTox_CID_3747
  • DSSTox_GSID_23747
  • DSSTox_RID_77182
  • Dideoxycytidine
  • EU-0100360
  • GTPL4828
  • HIVID
  • HMS1548B19
  • HMS1571O15
  • HMS2051H18
  • HMS2090C12
  • HMS2098O15
  • HMS2236N08
  • HMS3261G21
  • HMS3715O15
  • HSDB 7156
  • HY-17392
  • Hivid(TM)
  • Interferon AD + ddC
  • J-700276
  • KS-1130
  • LP00360
  • Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine
  • Lopac0_000360
  • MFCD00012188
  • MLS000069636
  • MLS000759540
  • MLS001055363
  • MLS001424210
  • MLS006011951
  • NC00300
  • NCGC00090705-01
  • NCGC00090705-02
  • NCGC00090705-03
  • NCGC00090705-05
  • NCGC00090705-06
  • NCGC00090705-07
  • NCGC00090705-08
  • NCGC00090705-09
  • NCGC00090705-10
  • NCGC00090705-11
  • NCGC00090705-13
  • NCGC00090705-15
  • NCGC00090705-24
  • NCGC00090705-25
  • NCGC00179242-01
  • NCGC00257202-01
  • NCGC00259204-01
  • NCGC00261045-01
  • NSC 606170
  • NSC-606170
  • NSC-759655
  • NSC606170
  • NSC759655
  • PC-SOD & ddC
  • Pharmakon1600-01502360
  • Prestwick0_001037
  • Prestwick1_001037
  • Prestwick2_001037
  • Prestwick3_001037
  • Q-201941
  • Q2344582
  • Ro 24-2027/000
  • Ro-24-2027/000
  • Ro-24-2027000
  • Ro-242027000
  • Ro-242027000/Ro-24-2027-000
  • SDCCGSBI-0050348.P002
  • SMR000058253
  • SR-01000075822
  • SR-01000075822-1
  • SR-01000736919
  • SR-01000736919-5
  • SRI-7707
  • SRI-7707-13
  • SRI-7707-14
  • SRI-7707_15
  • SRI-7707_17
  • SW197364-4
  • Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine
  • TimTec1_004969
  • Z1550648753
  • Zalcitabine
  • Zalcitabine (JAN/USP/INN)
  • Zalcitabine, 2'3'-Dideoxycytidine
  • Zalcitabine- Bio-X
  • Zalcitibine
  • bmse000712
  • ddC
  • ddC & GM-CSF
  • ddC & IFN.alpha.
  • ddC & Interferon.alpha.
  • ddC & NP (from PHCA or HSA)
  • ddC & sCD4
  • ddC;Dideoxycytidine;2',3'-Dideoxycytidine
  • ddCyd
  • dideoxycytidine (DDC)
  • s1719
  • zalcitabine

Reference codes for other databases

There exist several different chemical codes commonly used in orded to identify molecules:
  • ZINC39906
  • CAS-7481-89-2
  • UNII-6L3XT8CB3I
  • AKOS015854844
  • AKOS015894505
  • DTXSID0023747
  • CHEMBL853
  • CHEBI:10101
  • Tox21_113491
  • Tox21_201655
  • Tox21_303169
  • Tox21_500360
  • Tox21_113491_1
  • SPBio_003104
  • UPCMLD-DP115
  • UPCMLD-DP115:001
  • SCHEMBL3598

Physico-Chemical properties

IUPAC name4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Molecular formulaC9H13N3O3
Molecular weight211.218
Melting point (ºC)
Boiling point (ºC)
Density (g/cm3)
Molar refractivity53.52
LogP0.1
Topological polar surface area90.4

LogP and topological polar surface area (TPSA) values were estimated using Open Babel software.

The n-octanol/water partition coeficient (Kow) data is applied in toxicology and drug research. Kow values are used, to guess the environmental fate of persistent organic pollutants. High partition coefficients values, tend to accumulate in the fatty tissue of organisms. Molecules with a log(Kow) (or LogP) greater than 5 are considered to bioaccumulate.

TPSA values are the sum of the surface area over all polar atoms or molecules, mainly oxygen and nitrogen, also including hydrogen atoms.

In medicinal chemistry, TPSA is used to assess the ability of a drug to permeabilise cells.

For molecules to penetrate the blood-brain barrier (and act on receptors in the central nervous system), TPSA values below 90 Å2 are required. Thus, molecules with a polar surface area greater than 140 Å2 tend to be poorly permeable to cell membranes.